AstraZeneca touts new Russian plant as boon for emerging markets sales

Emerging markets have been a beacon for AstraZeneca ($AZN) CEO Pascal Soriot as he pilots the U.K. drugmaker through its challenges. And he now has a new production facility in Russia to draw on, although that market is less vibrant than it was four years ago when the project was launched. More from FiercePharma